Rentokil Initial reports 4.3% revenue growth in Q1 2026

Rentokil Initial plc

Rentokil Initial plc (LON:RTO) has issued a Trading Update for the first three months of the 2026 financial year covering the period 1 January 2026 to 31 March 2026.

Mike Duffy, Chief Executive of Rentokil Initial plc, said:

“We have made a good start to the year in a seasonally quieter first quarter, with continued momentum in North America and solid progress across our International businesses.

“In my first four weeks as CEO, I have been impressed with the depth of passion and pride that our people have in delivering exceptional customer service, and I am excited by the opportunity to unlock the potential of the Group.

“While geopolitical events, as previously noted, continue to create some uncertainty, the progress we report today gives us confidence in delivering a full year performance in line with market expectations.”

Group

Group Revenue for the quarter was $1,677m, up 4.3%. Organic Revenue growth was 3.4%.

North America

Revenue for the quarter was $995m, up 4.5%.  Organic Revenue growth was 3.9%. 

North America Pest Control Revenue growth was 4.7%.  Organic Revenue growth was 4.1%.

●    Pest Control Services Organic Revenue growth was 2.8% (2.6% in Q425), supported by robust price increases and good recovery of weather-related disruption in late January across the US. Performance through the quarter continued to benefit from our growth initiatives focused on enhancing marketing investments and improving sales execution. 

●   Business Services Organic Revenue growth was 12.7% (7.8% in Q425) supported by strong pre-spring demand in product distribution, contribution from 2025 new business wins in brand standards and high-value job work in lake management.

Colleague retention increased to 82.6% (FY25: 82.2%) and customer retention was broadly flat at 80.4% (FY25: 80.5%).

International (Group excluding North America)

Revenue for the quarter was $682m, up 4.1%.  Organic Revenue growth was 2.8%.

Good growth in Europe, Latin America and the UK & Sub-Saharan Africa was driven by strong pricing and growth in volumes. Pacific and MENAT were a 60bps headwind as the Pacific lapped strong comparatives in Rural and Trackspray, and MENAT experienced disruption from the Middle East conflict.

Category Performance

Pest Control Organic Revenue growth was 3.7%, with 4.1% growth in North America and 2.8% growth in International (3.0% excluding MENAT).

Hygiene & Wellbeing Organic Revenue grew by 2.1%, with 2.7% in International and a decline of (2.7)% in North America, impacted by a later phasing of construction timelines delaying Ambius jobbing revenue.   

M&A

The Group’s bolt-on M&A programme continued to create value with 9 deals, delivering annualised revenue in the year before acquisition of $19m.

Conference Details

Today, 16 April, at 9:00am BST, Rentokil Initial Chief Financial Officer, Paul Edgecliffe-Johnson will host a conference call for analysts and investors. A replay will be available on the Company website (https://www.rentokil-initial.com/investors.aspx) following the event.

To access the live audio webcast, register via the following link:

https://www.netroadshow.com/events/login/LE9zwo494GfiEWkBjeE6pecNQUQqzstvPAu

Alternatively, to join via teleconference, please register in advance using the link below:

https://www.investis-live.com/rentokil/69ca82a0fed46a000febe69d/mfbe

Share on:

Latest Company News

IBM-SLA breach strengthens the case for data-level encryption

The IBM-SLA breach shows why organisations may need to protect sensitive information directly, keeping it encrypted even when systems or accounts are compromised.

Time Finance adds experienced manager to support invoice finance clients

Time Finance has expanded its invoice finance team with an experienced relationship manager covering clients primarily across the Midlands.

RM Technology expands UK schools offering through Digital Poverty Alliance Partnership

RM Technology has partnered with the Digital Poverty Alliance to help UK schools fund and deliver one-to-one student device programmes.

Markets face a new test from rates, oil and AI valuations

Markets enter the second half of 2026 facing higher rate expectations, renewed oil risks and a tougher test for AI-related valuations.

Talking Medicines highlights strategic value of patient journey intelligence

Patient journey intelligence can help healthcare organisations identify care barriers and design more responsive pathways around real patient experiences.

Verici Dx adds senior transplant experts to support clinical development

Verici Dx has expanded its Scientific Advisory Board with 14 senior transplant and clinical research specialists to support product development and adoption.

    Search